| Literature DB >> 35517331 |
Andre Cook1,2, Timothy W Jones2, Jacob Tse-Wei Wang2, Hua Li3, Rob Atkin3, Noel W Duffy4, Scott W Donne1, Gregory J Wilson2.
Abstract
Defects at discontinuities of the perovskite lattice limit the performance of the perovskite solar cell (PSC). Lead iodide (PbI2) and pyridine have been shown to passivate these defects. We treat methylammonium lead iodide (MAPbI3) films with pyridine solutions to investigate the effects of the two passivators. By comparing confocal fluorescence microscopy (CFM) images at 405 nm excitation and then at 559 nm excitation we demonstrate the pyridine treatment passivates and forms PbI2 crystallites which cause additional passivation. This journal is © The Royal Society of Chemistry.Entities:
Year: 2020 PMID: 35517331 PMCID: PMC9054832 DOI: 10.1039/d0ra04641h
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1PL enhancement with increasing pyridine treatment concentration on MAPbI3. Normalized to the peak height of the control sample. Performed at 532 nm excitation. 1 M treatment spectra is presented in the ESI.†
Fig. 2XRD patterns for the pyridine treated MAPbI3 samples on FTO, whole patterns for all samples (a) and an expanded region surrounding the 12.7° PbI2 peak (b).
Fig. 3Top – AFM morphology and CPD of control and 100 mM pyridine treated films. Note the difference in voltage scale between the CPD images. Bottom – roughness and CPD plots for the pyridine treated films. With the average surface CPD (Av V) and the difference between the highest and lowest potentials (delta V).
Fig. 4CFM images of 100 mM pyridine treated MAPbI3 at 559 nm excitation (left) and 405 nm excitation (right). The perovskite emission band 700–800 nm is in grey and the PbI2 emission band 490–540 nm is in yellow. The blue highlighted region shows a PbI2 grain in the film and the larger red highlighted region shows passivating PbI2 on the film.